BioSpace News Archive

Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today the organization has surpassed two significant, biotechnology industry milestones: earning 101 patents issued; and filing over 200 patents in 20 countries worldwide.

New and updated pivotal data from the TECENTRIQ lung program, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer

Achieve Life Sciences, Inc. today announced that cytisine data will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference , September 6-8th in Munich, Germany.

European Immuno-Oncology Consortium to present update on TMB standardization efforts and clinical research data derived from new Oncomine Tumor Mutation Load Assay workflow

Laura and John Arnold Foundation, Peterson Center on Healthcare and Gary and Mary West Foundation Each Commit $10 Million to New, Not-for-Profit Generic Drug Company

Hereditary Neuropathy Foundation (HNF) today announced it is conducting a ground-breaking Externally-led Patient-Focused Drug Development Meeting (PFDD) for Charcot-Marie-Tooth Disease (CMT) and Inherited Neuropathies (IN) on Friday, September 28, 2018 at the College Park Marriott Hotel and Conference Center in Hyattsville, MD.

Vizient, Inc. today released its report “The Beat Goes On: Weighing Clinical Benefits, Patient Selection and Healthcare Economics of MRI-Compatible Cardiac Rhythm Devices”, which discusses the financial impact to hospitals resulting from the sudden and dramatic increase in the use of MRI-compatible CRM devices over the last 18 months.

Sage Therapeutics today announced that, on September 4, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 145,000 shares of its common stock to 63 new employees under Sage’s 2016 Inducement Equity Plan.

Merrimack Pharmaceuticals, Inc. today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.

Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist.